MRI With C13 Pilot Study Prostate Cancer
A Pilot Study to Evaluate the Reproducibility of Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) and Its Ability to Reflect Treatment Effects in Patients With Prostate Cancer
Sponsor: University of California, San Francisco
Terminated
Low accrual
Other terminated trials from University of California, San Francisco
- Hypertension · Phase PHASE2 · Jan 2026
- Menstrual Irregularity · Phase PHASE4 · Sep 2025
- Diabetes Mellitus, Type 2 · Phase NA · Feb 2025
- Asthma · Phase PHASE4 · Feb 2025
- Stone, Kidney · Phase NA · Dec 2024
See all terminations from University of California, San Francisco
Other Prostate Cancer trials with similar outcome
Listed as NCT02450201, this EARLY_PHASE1 trial focuses on Prostate Cancer and remains terminated or withdrawn. Sponsored by University of California, San Francisco, it has been updated 7 times since 2016, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated EARLY_PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated EARLY_PHASE1
-
Nov 2018 — Jan 2021 [monthly]
Terminated EARLY_PHASE1
Status: Recruiting → Terminated · Phase: NA → EARLY_PHASE1
-
Jun 2018 — Nov 2018 [monthly]
Recruiting NA
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Oct 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of California, San Francisco
For direct contact, visit the study record on ClinicalTrials.gov .